Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Sen, Sounok ^a   Wang, Shi Yi ^a,b   Soulos, Pamela R ^a,b   Frick, Kevin D ^c   Long, Jessica B ^a,b   Roberts, Kenneth B ^a,b   Yu, James B ^a,b   Evans, Suzanne B ^a,b   Chagpar, Anees B ^a,b   Gross, Cary P ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; BRACHYTHERAPY; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISTANT METASTASIS; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RACE; RECURRENCE FREE SURVIVAL; SENSITIVITY ANALYSIS; SURVIVAL TIME; VERY ELDERLY; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; MEDICARE; PATHOLOGY; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; TUMOR RECURRENCE; UNITED STATES;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; BREAST NEOPLASMS; COMORBIDITY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMANS; LIFE EXPECTANCY; MEDICARE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; SAMPLING STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84898741283     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju008     Document Type: Article

References (40)

1. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106.
2. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971-977.
3. Hughes KS, Schnaper LA, Cirrincione C, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol. 2010;28(Suppl.15s):abstract 507.
4. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575.
5. Njeh CF, Saunders MW, Langton CM. Accelerated partial breast irradiation (APBI): a review of available techniques. Radiat Oncol. 2010;5:90.
6. Aristei C, Palumbo I, Cucciarelli F, et al. Partial breast irradiation with interstitial high-dose-rate brachytherapy in early breast cancer: results of a phase II prospective study. Eur J Surg Oncol. 2009;35(2):144-150.
7. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345(19):1378-1387.
8. Abbott AM, Habermann EB, Tuttle TM. Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States. Cancer. 2011;117(15):3305-3310.
9. Carlson RW, McCormick B. Update: NCCN breast cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005;3(Suppl 1):S7-S11.
10. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9(2):136-222.
11. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387.
12. Soulos PR, Yu JB, Roberts KB, et al. Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol. 2012; 30(14):1601-1607.
13. Roberts KB, Soulos PR, Herrin J, et al. The adoption of new adjuvant radiation therapy modalities among medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phys. 2012; 85(5):1186-1192.
14. Suh WW, Pierce LJ, Vicini FA, et al. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for earlystage breast cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):790-796.
15. Hattangadi JA, Taback N, Neville BA, et al. Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst. 2012;104(1):29-41.
16. Smith GL, Xu Y, Buchholz TA, et al. Brachytherapy for accelerated partialbreast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol. 2011;29(2):157-165.
17. Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103(4):362-368.
18. Shaitelman SF. Sounding a warning bell? Documentation of the increased utilization of accelerated partial breast irradiation. J Natl Cancer Inst. 2012;104(1):5-7.
19. Smith GL, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012;307(17):1827-1837.
20. Presley CJ, Soulos PR, Herrin J, et al. Patterns of use and short-term complications of breast brachytherapy in the national Medicare population from 2008-2009. J Clin Oncol. 2012; 30(35):4302-4307.
21. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254-264.
22. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys. 2012;82(2):715-723.
23. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178.
24. Neumann PJ. What next for QALYs? JAMA. 2011;305(17):1806-1807.
25. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York: Oxford University Press; 2005.
26. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER- Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
27. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25-32.
28. Warren JL, Brown ML, Fay MP, et al. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20(1):307-316.
29. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
30. Hayman JA, Fairclough DL, Harris JR, et al. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol. 1997;15(3):1252-1260.
31. Folland S, Goodman AC, Stano M. The Economics of Health and Health Care. 5th ed. Upper Saddle River, NJ: Pearson Prentice Hall; 2007.
32. Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective costeffectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98(11):774-782.
33. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
34. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of costeffectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290-308.
35. Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. J Health Econ. 2008;27(5):1224-1236.
36. Cohen HJ, Lan L, Archer L, et al. Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803). J Geriatr Oncol. 2012;3(2):82-89.
37. Mohile SG, Heckler C, Fan L, et al. Age-related differences in symptoms and their interference with quality of life in 903 cancer patients undergoing radiation therapy. J Geriatr Oncol. 2011;2(4):225-232.
38. Evans SB, Kaufman SA, Price LL, et al. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: incidence, pathologic anatomy, and contributing factors. Int J Radiat Oncol Biol Phys. 2006;65(2):333-339.
39. Ravi A, Lee S, Karsif K, et al. Intraoperative placement of MammoSite for breast brachytherapy treatment and seroma incidence. Brachytherapy. 2010;9(1):76-80.
40. SEER Cancer Statistics Review. http://seer.cancer.gov/csr/1975-2005/ results-merged/sect-04-breast.pdf. Accessed January 10, 2013.